Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Peter Powers"'
Publikováno v:
Thrombosis Research. 114:161-165
Patients who are receiving warfarin therapy require frequent blood testing to monitor the intensity of anticoagulation. Although previous studies suggest that capillary blood monitoring of the international normalize ratio (INR) is rapid and reliable
Autor:
Derek King, Julian Dobranowski, Gordon H. Guyatt, Alicia Sarabia, Peter Powers, Deborah J. Cook, Hui N. Lee, Annette McCallum, Rose Hatala
Publikováno v:
Journal of General Internal Medicine. 10:342-345
To determine the adequacy of initial anticoagulation by intravenous heparin for patients who have deep venous thrombosis (DVT), and the factors that influence delayed anticoagulation, independent, duplicate chart review of 63 consecutive patients who
Autor:
Jeffrey I. Weitz, Franco Piovella, Jack Hirsh, Jacques R. Leclerc, Peter Powers, Mark Levine, Jeffrey S. Ginsberg, William Geerts, Alexander G.G. Turpie, Michael Gent, Jean Neemeh
Publikováno v:
Thrombosis and Haemostasis. 74:606-611
SummaryThe optimal duration of oral anticoagulant therapy for patients with acute proximal deep vein thrombosis (DVT) is uncertain. Based on the hypothesis that a normal impedance plethysmogram (IPG) following DVT defines a group of patients at low r
Autor:
Peter Powers
Publikováno v:
Men and Masculinities. 2:354-356
Autor:
Louis Desjardins, Jean Cusson, William Brien, Jack Hirsh, Jeffrey I. Weitz, Michael Gent, Jeanine Kassis, Jacques R. Leclerc, Peter Powers, Alexander G.G. Turpie, Moira Cruickshank, Jeffrey S. Ginsberg, Andrew R. Willan, Mark Levine, David C. Anderson, Christine Demers, Susan Haley, Michael J. Kovacs, William Geerts
Publikováno v:
The New England journal of medicine. 334(11)
Patients with acute proximal deep-vein thrombosis are usually treated first in the hospital with intravenous standard (unfractionated) heparin. However, the longer plasma half-life, better bioavailability after subcutaneous administration, and more p
Autor:
Mark Levine, Jacques R. Leclerc, Peter Powers, Jeffrey S. Ginsberg, William Geerts, Michael Gent, Alexander G.G. Turpie, Jean Neemeh, Richard M. Jay, Jack Hirsh
Publikováno v:
Circulation. 93(1)
Background The study objective was to determine the relative efficacy and safety of a low-molecular-weight heparinoid (Orgaran) compared with aspirin for the prevention of postoperative venous thromboembolism in patients undergoing surgery for fractu
Autor:
Robert Côté, Peter Powers, Turpie Ag, Jeffrey S. Ginsberg, Richard M. Jay, Michael Gent, William Geerts, Jacques R. Leclerc, Jean Neemeh, Mark Levine
Publikováno v:
Annals of internal medicine. 117(5)
Objective To compare the relative safety and efficacy of a low-molecular-weight heparinoid (ORG 10172) with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Design Double-blind randomized trial.
Autor:
Peter Powers
Publikováno v:
African American Review. 34:661
Autor:
Peter Powers, George Hutchinson
Publikováno v:
South Atlantic Review. 62:166
Autor:
Alexander G.G. Turpie, Andrew R. Willan, Jeffrey I. Weitz, Peter Skingley, Michael Gent, Mark Levine, Jack Hirsh, Jean Neemeh, Peter Powers
Publikováno v:
Archives of Internal Medicine. 156:851
Background: Deep vein thrombosis is common in patients undergoing major knee surgery. Static graduated compression stockings effectively prevent venous thrombosis in general surgery. Because of the demonstrated prophylactic efficacy of pneumatic comp